Medullary thyroid cancer prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 25: | Line 25: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Endocrine system]] | [[Category:Endocrine system]] | ||
[[Category:Endocrinology]] | |||
[[Category:Otolaryngology]] | |||
[[Category:Disease]] | |||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category: | [[Category:Types of cancer]] | ||
[[Category:Hereditary cancers]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 16:34, 16 November 2015
Medullary thyroid cancer Microchapters |
Differentiating Medullary thyroid cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Medullary thyroid cancer prevention On the Web |
American Roentgen Ray Society Images of Medullary thyroid cancer prevention |
Risk calculators and risk factors for Medullary thyroid cancer prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of serum calcitonin, serum calcium, serum parathyroid hormone, and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer.
Prevention
Surveillance of medullary thyroid cancer | |
---|---|
Serum calcium level annually for people diagnosed with multiple endocrine neoplasia type 2A | |
Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually | |
Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/[1] |
References
- ↑ Jessica Marquard & Charis Eng (1993). "Multiple Endocrine Neoplasia Type 2". PMID 020301434.